305
Participants
Start Date
March 31, 2011
Primary Completion Date
December 31, 2012
Study Completion Date
December 31, 2014
Placebo
Normal Saline, Intravenous, 0mg, Once a week for the first two weeks and every other week thereafter, 7 Weeks
Placebo
Normal Saline, Intravenous, 0 mg, Every other week, Up to 757 days
Anti-IP-10 Antibody
Solution for IV administration, Intravenous, 15 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks
Anti-IP-10 Antibody
Solution for IV administration, Intravenous, 25 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks
Anti-IP-10 Antibody
Solution for IV administration, Intravenous, 5 mg/kg, Every other week, Up to 757 days
Anti-IP-10 Antibody
Intravenous, Solution for IV administration, 10 mg/kg, Every other week, Up to 757 days
Anti-IP-10 Antibody
Intravenous, Solution for IV administration, 20 mg/kg, Every other week, Up to 757 days
Anti-IP-10 Antibody
Intravenous, Solution for IV administration, 15 mg/kg or optimal dose, Every other week. Open
Local Institution, Budapest
Local Institution, Vienna
Local Institution, Budapest
Local Institution, Concord
Local Institution, Garran
Local Institution, Edegem
Local Institution, Bonheiden
Local Institution, Parkville
Local Institution, Debrecen
Local Institution, Herston
Local Institution, Overport
Local Institution, South Brisbane
Local Institution, Szeged
Local Institution, Fremantle
Local Institution, Panorama
Local Institution, Paarl
Local Institution, Claremont
Local Institution, Graz
Mount Sinai School Of Medicine, New York
Long Island Clinical Research Assoc., Llp, Great Neck
Local Institution, Mexico City
Local Institution, Botucatu
Local Institution, San Donato Milanese (mi)
Local Institution, Hamburg
Metropolitan Gastroenterology Group, Pc, Chevy Chase Cr, Chevy Chase
Local Institution, Rio de Janeiro
Local Institution, Kiel
University Of North Carolina At Chapel Hill, Chapel Hill
Charlotte Gastroenterology & Hepatology, Pllc, Charlotte
Atlanta Gastroenterology Associates, Atlanta
University Of Florida, Gainesville
Shafran Gasteroenterology Center, Winter Park
Local Institution, Pessac
Local Institution, Padua
Nashville Medical Research Institute, Nashville
University Of Louisville, Louisville
University Of Kentucky, Lexington
Local Institution, Guadalajara
Local Institution, Guadalajara
Consultants For Clinical Research, Cincinnati
Gastroenterology Research Of Lima, Lima
Local Institution, Münster
Local Institution, Münster
Local Institution, Vandœuvre-lès-Nancy
Minnesota Gastroenterology, Pa, Plymouth
Local Institution, Lille
Westglen Gastrointestinal Consultants, Lee's Summit
Local Institution, Monterrey
Health Science Research Center, Pratt
Gastroenterology Research Of New Orleans, Hammond
Local Institution, San Giovanni Rotondo (fg)
Local Institution, Goiânia
Gastroenterology Research Of Tyler (Gerty), Tyler
Gastroenterology Research Of San Antonio, San Antonio
Western States Clinical Research Inc., Wheat Ridge
Santa Monica Research Institute, Santa Monica
Local Institution, Veracruz
University Of California, San Diego, La Jolla
Local Institution, Clichy
Pharma Resource, East Providence
Local Institution, Leuven
Local Institution, Calgary
Local Institution, Vancouver
Local Institution, Kingston
Local Institution, Vaughan
Local Institution, Nice
Local Institution, Roma
Local Institution, Mexico, D. F.
Local Institution, Amsterdam
Local Institution, Amsterdam
Local Institution, Rotterdam
Local Institution, Rzeszów
Local Institution, Sosnowiec
Local Institution, Warsaw
Local Institution, Warsaw
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY